Identifying the most appropriate pathogenic pathways—by inhibiting IL-5 in patients with eosinophilic phenotypes, IL-4/IL-13 in severe T helper 2 (Th2)-type asthma, or IgE inhibitors for allergic asthma—has led to substantial progress in disease control, with broader possibilities for blocking the inflammatory process. This evidence concerns the gene IL5 and asthma.